`
NEW YORK, March 10, 2025 — The Gross Law Firm is notifying ESSA Pharma Inc. (NASDAQ: EPIX) shareholders of the following information.
The firm encourages shareholders who acquired EPIX shares during the specified period to get in touch regarding the possibility of being appointed as a lead plaintiff. You don’t have to be a lead plaintiff to receive any potential compensation.
CONTACT US HERE:
CLASS PERIOD: December 12, 2023 to October 31, 2024
ALLEGATIONS: The lawsuit alleges that throughout the class period, the defendants made materially incorrect and/or deceptive claims and/or neglected to reveal that: (i) the combination of masofaniten and enzalutamide did not demonstrate a significant improvement in efficacy compared to enzalutamide alone; (ii) consequently, the combination of masofaniten and enzalutamide was not as effective in treating prostate cancer as the defendants had led investors to believe; (iii) the M-E Combination Study, which examined monotherapy and combination therapy for prostate cancer treatment, was unlikely to achieve its predetermined Phase 2 primary endpoint; (iv) therefore, the defendants had overstated the clinical, regulatory, and commercial potential of masofaniten; and (v) as a result, the defendants’ public statements were materially false and misleading during the relevant period.
DEADLINE: March 25, 2025 Shareholders should register for this class action without delay. Register your information here:
NEXT STEPS FOR SHAREHOLDERS: Upon registering as a shareholder who purchased EPIX shares during the specified period, you will be enrolled in portfolio monitoring software that will keep you informed on the case’s progress. The deadline to apply for lead plaintiff status is March 25, 2025. Participation in this case is free and without obligation.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized leader in class action lawsuits with a mission to protect investors’ rights from damages caused by deception, fraud, and unlawful business conduct. The Gross Law Firm is dedicated to promoting responsible business practices and good corporate citizenship. The firm aims to recover losses on behalf of investors when a company’s false and/or misleading statements or omission of important information artificially inflates the company’s stock price. Attorney advertising. Past outcomes do not guarantee similar results.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email:
Phone: (646) 453-8903
SOURCE The Gross Law Firm